
Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License Application 01 December 2022
NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
Oslo Norway, November 18, 2022. The LINK Medical Board is pleased to announce the appointment of Sissel... Read more
ViroGates announces the emergency use authorisation of Kineret treatment for COVID-19 related pneumonia... Read more
COPENHAGEN, Denmark, Nov. 10, 2022 /PRNewswire/ — Breye Therapeutics ApS (Breye), a clinical-stage... Read more
NEW YORK, Oct. 28, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
Copenhagen, 25th October 2022 Gubra i Hørsholm vinder EY Entrepreneur Of The Year 2022 i region Sjælland... Read more
Malmö, October 11, 2022 PILA PHARMA AB (publ) (FN STO: PILA) today publishes that a 13-week oral safety... Read more
NEW YORK, Oct. 03, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
As part of being able to document and communicate the importance of the pharmaceutical and biotech industry... Read more